Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;4:378–90.

Article  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: a subanalysis of the REFLECT study. J Hepatol. 2023;1:133–41.

Article  Google Scholar 

Buttell A, Qiu W. The action and resistance mechanisms of Lenvatinib in liver cancer. Mol Carcinog. 2023;12:1918–34.

Article  Google Scholar 

Sarkar C, Chakroborty D, Goswami S, Fan H, Mo X and Basu S. VEGF-A controls the expression of its regulator of angiogenic functions, dopamine D2 receptor, on endothelial cells. J Cell Sci. 2022; 11.

Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014; 18.

Zschabitz S and Grullich C. Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRalpha, KIT and RET. Recent Results Cancer Res. 2018; 187–98.

Wang Y, Peng C, Wang G, Xu Z, Luo Y, Wang J, et al. Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. Chem Biol Drug Des. 2019;5:934–48.

Article  Google Scholar 

Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;6:2641–53.

Article  Google Scholar 

Prieto-Dominguez N, Shull AY, Teng Y. Making way for suppressing the FGF19/FGFR4 axis in cancer. Future Med Chem. 2018;20:2457–70.

Article  Google Scholar 

Johansson H, Sondergaard J N, Jorns C, Kutter C and Ellis E C S. Chenodeoxycholic Acid Modulates Bile Acid Synthesis Independent of Fibroblast Growth Factor 19 in Primary Human Hepatocytes. Front Endocrinol (Lausanne). 2020; 554922.

Phan P, Saikia BB, Sonnaila S, Agrawal S, Alraawi Z, Kumar TKS, et al. The saga of endocrine FGFs. Cells. 2021;9:2418.

Article  Google Scholar 

Shibata O, Kamimura K, Ko M, Sakai N, Abe H, Morita S, et al. Effect of lenvatinib on a hepatocellular carcinoma with fibroblast growth factor receptor 4 expression: a case report and review of the literature. Intern Med. 2021;11:1709–15.

Article  Google Scholar 

Zhang K, Chu K, Wu X, Gao H, Wang J, Yuan YC, et al. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res. 2013;4:1298–307.

Google Scholar 

Iseda N, Itoh S, Toshida K, Tomiyama T, Morinaga A, Shimokawa M, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. Cancer Sci. 2022;7:2272–87.

Article  Google Scholar 

Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021;5:2544–60.

Article  Google Scholar 

Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;7869:730–4.

Article  Google Scholar 

Hoshi T, Watanabe Miyano S, Watanabe H, Sonobe RMK, Seki Y, Ohta E, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun. 2019;1:1–7.

Article  Google Scholar 

Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009;11:1777–83.

Article  Google Scholar 

Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014; 638747.

Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;1:97–103.

Article  Google Scholar 

Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4871 patients. Clin Cancer Res. 2017;8:1988–97.

Article  Google Scholar 

Yamada T, Fujiwara N, Kubota N, Matsushita Y, Nakatsuka T, Kurosaki S, et al. Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma. Hepatol Commun. 2023; 8.

Mei Z, Gao X, Pan C, Wu Q, Wang S, Qian J, et al. Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2. Cancer Sci. 2023;4:1284–96.

Article  Google Scholar 

Sun Q, Shen M, Zhu S, Liao Y, Zhang D, Sun J, et al. Targeting NAD(+) metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression. Hepatol Int. 2023;6:1444–60.

Article  Google Scholar 

Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, et al. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med. 2021;22:7977–87.

Article  Google Scholar 

Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;12:3993–4002.

Article  Google Scholar 

Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy. Semin Liver Dis. 2018;4:379–88.

Article  Google Scholar 

Nagai H, Mukozu T, Kobayashi K, Nogami A, Nagumo H, Mohri K, et al. Lenvatinib might induce activation of host immunity in patients with hepatocellular carcinoma. Oncology. 2023;1:32–40.

Article  Google Scholar 

Adachi Y, Matsuki M, Watanabe H, Takase K, Kodama K, Matsui J, et al. Antitumor and antiangiogenic activities of lenvatinib in mouse xenograft models of vascular endothelial growth factor-induced hypervascular human hepatocellular carcinoma. Cancer Invest. 2019;4–5:185–98.

Article  Google Scholar 

Ogasawara S, Mihara Y, Kondo R, Kusano H, Akiba J, Yano H. Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo. Anticancer Res. 2019;11:5973–82.

Article  Google Scholar 

Muraishi N, Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, et al. The impact of lenvatinib on tumor blood vessel shrinkage of hepatocellular carcinoma during treatment: an imaging-based analysis. Oncology. 2023;2:134–44.

Article  Google Scholar 

Ueshima E, Sofue K, Takaki H, Hirata Y, Kodama H, Okada T, et al. Lenvatinib mitigates transarterial embolization-induced polarization of tumor-associated macrophages in a rat hepatocellular carcinoma model. J Vasc Interv Radiol. 2023;11(1977–85): e4.

Google Scholar 

Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, et al. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol. 2021;6:60.

Article  Google Scholar 

Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma. Front Immunol. 2022;13:896752.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;1:28.

Article  Google Scholar 

Lau G, Abou-Alfa G K, Cheng A L, Sukeepaisarnjaroen W, Dao T V, Kang Y K, et al. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J Hepatol. 2024.

Melero I, Yau T, Kang YK, Kim TY, Santoro A, Sangro B, et al. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Ann Oncol. 2024;6:537–48.

Article  Google Scholar 

O’Donnell J S, Madore J, Li X Y and Smyth M J. Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol. 2020; 189–96.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;10088:2492–502.

Article  Google Scholar 

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;1:77–90.

Article  Google Scholar 

El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, et al. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2024;4:381–91.

Article  Google Scholar 

Kudo M, Finn R S, Edeline J, Cattan S, Ogasawara S, Palmer D H, et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022; 1–12.

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind phase III trial. J Clin Oncol. 2020;3:193–202.

Article  Google Scholar 

Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind phase III trial. J Clin Oncol. 2023;7:1434–43.

Article  Google Scholar 

Torrens L, Montironi C, Puigvehi M, Mesropian A, Leslie J, Haber PK, et al. Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology. 2021;5:2652–69.

Article  Google Scholar 

Yang J, Guo Z, Song M, Pan Q, Zhao J, Huang Y, et al. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma. Front Immunol. 2023;14:1212577.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2020;4:1247–61.

Article  Google Scholar 

Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, et al. Inhibition of FGFR reactivates IFNgamma signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res. 2022;2:292–306.

Article  Google Scholar